 NEW YORK and CLEVELAND, July 07, 2021 GLOBE NEWSWIRE -- Abeona Therapeutics Inc. Nasdaq: ABEO, a fully-integrated leader in gene and cell therapy, today announced updated Phase 12a clinical trial results up to six years following treatment with Abeonas investigational EB-101 for recessive dystrophic epidermolysis bullosa RDEB. The data showed that investigator assessment of wound healing of 50 or greater from baseline was present in 69 of treated wounds n1826 at 3 years, 93 n1415 at 4 years, 80 n1215 at 5 years, and 80 n45 at 6 years. The results were reported in a poster, titled Long-Term Healing, Pain Reduction, and Patient-Reported Outcomes in Recessive Dystrophic Epidermolysis Bullosa Following EB-101 Treatment of Large, Chronic Wounds, at the Society for Pediatric Dermatology SPD 46th Annual Meeting. 